Skip to content
10-Q

Quarterly Report

TScan Therapeutics, Inc. TCRX

0001193125-25-275933

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2025 · Sep 30, 2025 129.84M sh
Shares Diluted Q3 2025 · Sep 30, 2025 129.75M sh
Shares Diluted Q3 2025 · Sep 30, 2024 118.7M sh
Shares Diluted Q3 2025 · Sep 30, 2024 109.04M sh
Capex Q3 2025 · Sep 30, 2025 $4.24M
Capex Q3 2025 · Sep 30, 2024 $2.94M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$103.32M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$83.41M
Long Term Debt Q3 2025 · Sep 30, 2025 $32.41M
Long Term Debt Q3 2025 · Dec 31, 2024 $32.07M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $169.51M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $178.69M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $133.12M
Stockholders Equity Q3 2025 · Sep 30, 2025 $144.02M
Stockholders Equity Q3 2025 · Jun 30, 2025 $176.71M
Stockholders Equity Q3 2025 · Dec 31, 2024 $240.97M
Stockholders Equity Q3 2025 · Sep 30, 2024 $229.09M
Stockholders Equity Q3 2025 · Jun 30, 2024 $255.22M
Stockholders Equity Q3 2025 · Dec 31, 2023 $150.87M
Current Liabilities Q3 2025 · Sep 30, 2025 $29.21M
Current Liabilities Q3 2025 · Dec 31, 2024 $35.96M
Total Liabilities Q3 2025 · Sep 30, 2025 $118.2M
Total Liabilities Q3 2025 · Dec 31, 2024 $130.15M
Current Assets Q3 2025 · Sep 30, 2025 $188.17M
Current Assets Q3 2025 · Dec 31, 2024 $292.72M
Total Assets Q3 2025 · Sep 30, 2025 $262.23M
Total Assets Q3 2025 · Dec 31, 2024 $371.12M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.28
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.82
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.25
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.84
Eps Basic Q3 2025 · Sep 30, 2025 −$0.28
Eps Basic Q3 2025 · Sep 30, 2025 −$0.82
Eps Basic Q3 2025 · Sep 30, 2024 −$0.25
Eps Basic Q3 2025 · Sep 30, 2024 −$0.84
Sga Expense Q3 2025 · Sep 30, 2025 $7.87M
Sga Expense Q3 2025 · Sep 30, 2025 $25.6M
Sga Expense Q3 2025 · Sep 30, 2024 $7.41M
Sga Expense Q3 2025 · Sep 30, 2024 $22.26M
Rd Expense Q3 2025 · Sep 30, 2025 $31.69M
Rd Expense Q3 2025 · Sep 30, 2025 $94.11M
Rd Expense Q3 2025 · Sep 30, 2024 $26.26M
Rd Expense Q3 2025 · Sep 30, 2024 $78M
Net Income Q3 2025 · Sep 30, 2025 −$35.71M
Net Income Q3 2025 · Sep 30, 2025 −$106.79M
Net Income Q3 2025 · Sep 30, 2024 −$29.89M
Net Income Q3 2025 · Sep 30, 2024 −$91.69M
Operating Income Q3 2025 · Sep 30, 2025 −$37.05M
Operating Income Q3 2025 · Sep 30, 2025 −$111.96M
Operating Income Q3 2025 · Sep 30, 2024 −$32.62M
Operating Income Q3 2025 · Sep 30, 2024 −$98.11M
Revenue Q3 2025 · Sep 30, 2025 $2.51M
Revenue Q3 2025 · Sep 30, 2025 $7.76M
Revenue Q3 2025 · Sep 30, 2024 $1.05M
Revenue Q3 2025 · Sep 30, 2024 $2.15M